Forte Biosciences (FRA:37T) Total Operating Expense: €66.10 Mil (TTM As of Mar. 2026)


FRA:37T Forte Biosciences Inc FRA:37T
34 GF Score
Price €19.30
! 2 Warning Signs
View Full Analysis

What is Forte Biosciences Total Operating Expense?

Forte Biosciences FRA:37T +9.04% 34 Total Operating Expense is €66.10 Mil as of Mar. 2026. GuruFocus rates FRA:37T with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Forte Biosciences's Total Operating Expense for the three months ended in Mar. 2026 was €19.41 Mil. Forte Biosciences's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €66.10 Mil.

Forte Biosciences Total Operating Expense Related Terms

Forte Biosciences Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Forte Biosciences's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Forte Biosciences Total Operating Expense Chart

Forte Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 19.02 13.12 29.79 34.96 60.34

Forte Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.92 10.04 15.66 20.98 19.41
FRA:37T
34GF Score
Forte Biosciences Inc FRA:37T
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Forte Biosciences Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €66.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €66.10 Mil mean?
Forte Biosciences (FRA:37T) has a Total Operating Expense of €66.10 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Forte Biosciences and its competitors.
Is Forte Biosciences' Total Operating Expense too high?
Forte Biosciences' current Total Operating Expense is €66.10 Mil. Overall, Forte Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Forte Biosciences' Total Operating Expense compare to AUTL and SGMT?
Forte Biosciences' Total Operating Expense of €66.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Forte Biosciences and its competitors. Forte Biosciences's current Total Operating Expense is €66.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Forte Biosciences stock overvalued right now?
Forte Biosciences (FRA:37T) has a current Total Operating Expense of €66.10 Mil. The current Total Operating Expense is €66.10 Mil. Forte Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Forte Biosciences (FRA:37T), the current Total Operating Expense is €66.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Forte Biosciences Business Description

Other Exchanges FBRX:USA
Address 3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
34GF Score

Get the complete analysis for FRA:37T

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.30
Price